+

WO1997006158A1 - Derives d'amidine bicycliques utiles en therapie - Google Patents

Derives d'amidine bicycliques utiles en therapie Download PDF

Info

Publication number
WO1997006158A1
WO1997006158A1 PCT/GB1995/001896 GB9501896W WO9706158A1 WO 1997006158 A1 WO1997006158 A1 WO 1997006158A1 GB 9501896 W GB9501896 W GB 9501896W WO 9706158 A1 WO9706158 A1 WO 9706158A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
amino
nxy
methyl
Prior art date
Application number
PCT/GB1995/001896
Other languages
English (en)
Inventor
James Edwin Macdonald
William Calvin Shakespeare
Robert John Murray
James Russell Matz
Original Assignee
Astra Aktiebolag
Astra Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag, Astra Pharmaceuticals Limited filed Critical Astra Aktiebolag
Priority to PL95319576A priority Critical patent/PL319576A1/xx
Priority to KR1019970702315A priority patent/KR970706272A/ko
Priority to EE9700207A priority patent/EE9700207A/xx
Priority to CZ19971086A priority patent/CZ287969B6/cs
Priority to NZ290918A priority patent/NZ290918A/en
Priority to BR9509297A priority patent/BR9509297A/pt
Priority to SK390-97A priority patent/SK281442B6/sk
Priority to PCT/GB1995/001896 priority patent/WO1997006158A1/fr
Priority to TW084110522A priority patent/TW317565B/zh
Publication of WO1997006158A1 publication Critical patent/WO1997006158A1/fr
Priority to IS4452A priority patent/IS4452A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • This invention relates to bicyclic amidine derivatives, processes for their preparation, compositions containing them and their use in therapy.
  • amidine derivatives have been described for use in therapeutic applications.
  • N-Phenyl amidine derivatives have been described for use in the treatment of diabetes in US Patent No. 3669974 (USV Pharmaceutical Corp.) and UK Patent Application 2226562 (Boots).
  • N'N"disubstituted amidines are described for use in the treatment of hypertension, depression and hallucinogenic states in International Patent Application WO 92/04054 (University of Oregon).
  • the use of certain amidines and symmetric bisamidines as analgesics, in the treatment of inflammation and in the treatment of hypertension is described in Belgian Patent No. 717740 and UK Patent No. 1180629 (both of Delaisme).
  • Amidine derivatives have also been described for use as herbicides in German Patent Application DE-OS-2321330 (Bayer).
  • nitric oxide synthetase inhibitors in the treatment of disease has also been described, for example, in International Patent Applications WO 94/12163 (Abbott), WO 93/13066 and WO 94/12165 (both of Wellcome) and European Patent Applications 446699 (Merrell Dow), 547558 and 558468 (both of Washington University).
  • nitric oxide synthetase inhibitors in therapy is also described in WO 95/00505, WO 95/09619, WO 95/09621 (all of Wellcome), WO 95/10266 (Otsuka), WO 95/11231 and WO 95/11014 (both of Searle).
  • guanidine derivatives and amidine derivatives which are inhibitors of nitric oxide synthetase in the treatment inter alia of neurodegenerative disease (WO 94/21621. WO 95/05363).
  • D represents a five membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, N or S, optionally substituted at a carbon atom by halogen, trifiuoromethyl, alkyl Cl to 6, nitro or cyano, and which is connected to the remainder of the compound of formula I through a carbon atom;
  • A represents N(X) or CH(-(CH 2 ) m -NXY);
  • U represents NH, O or CH : ;
  • V represents (CH 2 ) a ;
  • W represents (CH 2 ) b ; a and b independently represent an integer 0 to 3, provided that a+b is in the range 1 to 3;
  • X and Y independently represent hydrogen, alkyl Cl to 6, or the group -(CH 2 ) tripod0, or -NXY represents piperidinyl, pyrrolidinyl. morpholinyl or tetrahydroisoquinolinyl;
  • Q represents biphenyl or phenyl optionally substituted by one or more groups selected from alkyl Cl to 6, alkoxy Cl to 6, perfluoroalkyl Cl to 6, halogen, nitro or cyano; m represents an integer 0 to 5; n represents an integer 0 to 6; or the chain U-V-A-W is as defined above save that it may be unsaturated, or the chain U-V-A-W may represent -NH-CH 2 -CH 2 -0- substituted at a carbon atom by the group -(CH 2 ) m -NXY, wherein m, X and Y are as defined above, and pharmaceutically acceptable salts thereof.
  • a preferred group of compounds of formula I is defined by formula IA:
  • T represents a C 3 . 5 saturated or unsaturated alkylene chain substituted by -(CH 2 ) m - NXY; -O-(CH 2 ) 2 -NH- substituted by -(CH 2 ) m -NXY; or -U-(CH 2 ) a -N(X)-(CH 2 ) b -;
  • X and Y independently represent hydrogen, alkyl Cl to 6, or the group -(CH 2 ) resortQ, or -NXY represents piperidinyl, pyrrolidinyl, morpholinyl or tetrahydroisoquinolinyl;
  • Q represents phenyl optionally substituted by alkyl Cl to 6, alkoxy Cl to 6, trifiuoromethyl.
  • halogen, nitro or cyano and U, m, n, a, b and D are as defined above, save that when T represents -U-(CH 2 ) a -N(X)-(CH 2 ) b - and X represents -(CH 2 ) sniffQ, n represents an integer 0 to 5, and pharmaceutically acceptable salts thereof.
  • D represents a five-membered heterocyclic aromatic ring containing one heteroatom selected from O, N or S, optionally substituted at a carbon atom by halogen.
  • D represents thienyl, furyl or pyrrolyl, especially thienyl or furyl. more especially thienyl and most especially 2- thienyl.
  • T represents a C 3.5 saturated or unsaturated alkylene chain substituted by -(CH 2 ) m -NXY, particularly a C 3.5 saturated alkylene chain substituted by -(CH 2 ) m -NXY, especially a C 3. saturated alkylene chain substituted by -(CH 2 ) m -
  • T represents a C ⁇ . s saturated or unsaturated alkylene chain substituted by -(CH 2 ) m -NXY; or -0-(CH 2 ) 2 -NH- substituted by -(CH 2 ) m -NXY
  • X and Y independently represent hydrogen, alkyl Cl to 6 or the group -(CH 2 ) n Q.
  • X and Y independently represent hydrogen, methyl, ethyl or the group -(CH 2 ) n Q and especially that one of X and Y represents hydrogen and the other represents hydrogen or the group -(CH 2 ) n Q.
  • m 0 or 1, especially 0.
  • T represents -U-(CH 2 ) a -N(X)-(CH 2 ) b -, we prefer that a+b is 1 or 2.
  • T represents -U-(CH 2 ) a -N(X)-(CH 2 ) b -
  • X represents hydrogen, alkyl Cl to 6 or the group -(CH 2 ) n Q.
  • n 0, 1 or 2, especially 1.
  • Q represents phenyl optionally substituted by alkyl Cl to 6 or halogen, although we particularly prefer that Q represents unsubstituted phenyl.
  • R 9 - L V I wherein R 9 represents alkyl Cl to 6 or the group -(CH 2 ) n Q and L is a leaving group; (d) preparing a compound of formula I in which A represents CH(-(CH 2 ) m -
  • NXY NXY
  • X and Y represents alkyl Cl to 6 or the group -(CH 2 ) n Q by reacting a corresponding compound of formula I in which one or both of X and
  • Y represents hydrogen with a compound of formula VI;
  • one of X and Y represents hydrogen, and the other represents -(CH 2 ) complicatQ in which n represents an integer 1 to 6, by reduction of a compound of formula XI
  • the reaction will take place on stirring a mixture of the reactants in a suitable solvent, for example a lower alkanol e.g. ethanol, isopropanol or tertiary butanol, at a temperature between room temperature and the reflux temperature of the solvent.
  • a suitable solvent for example a lower alkanol e.g. ethanol, isopropanol or tertiary butanol.
  • the reaction time will depend inter alia on the solvent and the nature of the leaving group, and may be up to 48 hours, however it will typically be from 1 to 5 hours.
  • Suitable leaving groups that L may represent include thioalkyl, sulphonyl, trifluorocarbon sulphonyl, halide, alkyl and aryl alcohols and tosyl groups; others are recited in 'Advanced Organic Chemistry', J. March (1985) 3rd Edition, McGraw-Hill on page 315 and are well known in the art.
  • the reaction is preferably performed by refluxing a mixture of the two compounds for several hours in the presence of a suitable solvent whereby the reaction temperature is high enough so that condensation takes place readily, but not sufficiently high to decompose the amidine formed.
  • the reaction temperature can vary from room temperature to about 250 °C, although it is preferable to perform the reaction at temperatures from about 100 °C to 200 °C.
  • o- dichlorobenzene is a particularly suitable solvent and it is useful to add 4- dimethylaminopyridine as a catalyst.
  • the solvent may be decanted, and the reaction worked up by addition of aqueous base.
  • the acid HA may be an organic or inorganic acid, for instance, hydrochloric, hydrobromic, hydroiodic, sulphuric, nitric, phosphoric, acetic, lactic, succinic. fumaric. malic, maleic, tartaric, citric, benzoic or methanesulphonic acid.
  • reaction will take place under standard conditions, for example by reacting the two compounds in an inert solvent under basic conditions at room temperature for a period of up to 12 hours.
  • L represents halide. particularly bromide.
  • Process (d) may be performed under conditions analogous to those described above for process (c).
  • the reduction may be perfomed by treatment with diborane in an inert solvent e.g. THF.
  • inert solvent e.g. THF
  • reagents which may be suitable include lithium aluminium hydride and reagents for catalytic hydrogenation e.g. H 2 on Pd/C. Further details of the reaction conditions for use of these reactions may be obtained by reference to J. March "Advanced Organic Chemistry" on page 1099, including the references cited therein.
  • the reduction reaction may be performed under a number of conditions, for example those described in J March "Advanced Organic Chemistry" on pages 1103-1104. These include catalytic hydrogenation, use of Zn, Sn or Fe metal, A1H 3 -A1C1 3 , sulphides and others. We prefer to perform the reaction by hydrogenation at atmospheric pressure for 3-6 hours in the presence of a palladium and carbon catalyst.
  • the reduction may be performed by treating the compound with sodium borohydride or sodium cyanoborohydride under standard conditions.
  • reaction may be performed under conditions analogous to those described above for process (e).
  • Salts of compounds of formula I may be formed by reacting the free base or a salt, enantiomer, tautomer or protected derivative thereof, with one or more equivalents of the appropriate acid.
  • the reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, eg water, dioxan. ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuo or by freeze drying.
  • the reaction may be a metathetical process or it may be carried out on an ion exchange resin.
  • the compounds of formula II may be prepared by reduction of a corresponding compound of formula XIII
  • the reduction reaction may be performed under analogous conditions to those described above for process (f).
  • Certain compounds of formula II are either known or may be prepared by conventional methods known per se.
  • Other compounds of formula II may be prepared from known compounds with simpler substituent groups by following analogous processes to those described above for processes (c) to (j).
  • analogous processes to those described above for processes (c) to (j).
  • process (j) we find it convenient to prepare certain compounds of formula XIII in which A represents CH(-NXY) and X represents hydrogen by reduction of the corresponding imine formed by reaction of a compound of formula NH 2 Y with the nitrated bicyclic ketone.
  • Compounds of formula IV may be prepared by analogous processes to those described for the preparation of compounds of formula II.
  • Compounds of formula IV may be converted to corresponding compounds of formula II by treatment with a base.
  • Compounds of formula II may be converted to corresponding compounds of formula IV by treatment with a protic acid HA. for example one of those listed above.
  • D is as defined above, with an alkyliodide.
  • Compounds of formula VII, VIII, IX, X, XI and XII may be prepared by analogous processes to those described for the preparation of compounds of formula I. Such compounds may be readily prepared from compounds with simpler substituent groups by conventional methods e.g. formation of an amide (VII, X) by reaction of an amine with a carboxylic acid or activated derivative thereof or formation of an imine (IX, XI, XII) by reaction of an amine with an aldehyde.
  • Compounds of formula V, VT, XIII and XIV are either known or may be prepared by conventional methods known per se.
  • the compounds of the invention and intermediates may be isolated from their reaction mixtures by standard techniques.
  • alkyl Cl to 6 includes straight chain, branched, saturated, unsaturated. aliphatic and cyclic alkyl groups containing 1 to 6 carbon atoms.
  • the compounds of formula I may exist in tautomeric. enantiomeric or diasteriomeric forms, all of which are included within the scope of the invention.
  • the various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, e.g. fractional crystallisation, or HPLC. Alternatively the individual enantiomers may be made by reaction of the appropriate optically active starting materials under reaction conditions which will not cause racemisation.
  • Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.
  • the compounds of formula I possess useful pharmacological activity in animals.
  • they possess useful nitric oxide synthetase inhibiting activity and are expected to be useful in the treatment or prophylaxis of human diseases or conditions in which the synthesis or oversynthesis of nitric oxide forms a contributory part; for example, hypoxia, e.g. in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia e.g.
  • pre-senile dementia Alzheimer's disease and AIDS-related dementia, Sydenham's chorea, Parkinson's disease, Tourette's Syndrome, Huntington's disease, Amyotrophic Lateral Sclerosis, Korsakoff s disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, autism, seasonal affective disorder, jet-lag, depression or other symptoms associated with
  • Premenstrual Syndrome Pain and anxiety.
  • Compounds of formula I may also be expected to show activity in the prevention and reversal of tolerance to opiates and diazepines. treatment of drug addiction, relief of pain and treatment of migraine and other vascular headaches.
  • the compounds of the present invention may also show useful immunosuppressive activity, be useful in the treatment or prophylaxis of inflammation, neurogenic inflammation, reversible obstructive airways disease including asthma and adult respiratory distress syndrome (ARDS), in the treatment of gastrointestinal motility disorders, cancer, in the induction of labour, for reduction of gastric acid secretion and for increasing the contractile force of skeletal muscle.
  • ARDS adult respiratory distress syndrome
  • Compounds of formula I are most particularly of interest in the treatment of neurodegenerative disorders, of migraine or for the prevention and reversal of tolerance to opiates and diazepines or for the treatment of drug addiction and especially in the treatment of neurodegenerative disorders.
  • a method of treatment or prophylaxis of one of the aforementioned diseases or conditions which comprises administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, to a person suffering from or susceptible to such a disease or condition.
  • the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered to a human at a daily dosage of between 1 mg and 2000 mg (measured as the solid form).
  • the compounds of formula I, and pharmaceutically acceptable salts thereof, may be used on their own. or in the form of appropriate medicinal preparations for enteral or parenteral administration.
  • a pharmaceutical formulation including preferably less than 80% and more preferably less than 50% of a compound of formula I. or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
  • nitric oxide synthetase has a number of isoforms and compounds of formula I, or pharmaceutically acceptable salts thereof, may be screened for nitric oxide synthetase activity by procedures based on those of Bredt and Snyder in Proc. Natl. Acad. Sci. ( 1990) 87, 682-685 and Forstermann et. al., Eur. J. Pharm. (1992) 225, 161-165 as follows.
  • Nitric oxide synthetase converts 3 H-L-arginine to 3 H-L- citrulline which can be separated by cation exchange chromatography and quantified by scintillation counting.
  • Enzyme was isolated from rat hippocampus or cerebellum.
  • the cerebellum or hippocampus of a male Sprague-Dawley rat (250-275g) is removed following CO 2 anaesthesia of the animal and decapitation.
  • Cerebellar or hippocampal supernatant is prepared by homogenisation in 50 mM Tris-HCl with 1 mM EDTA buffer (pH 7.2 at 25 °C) and centifugation for 15 minutes at 20,000 g. Residual L-arginine is removed from the supernatant by chromatography through Dowex AG-50W-X8 sodium form and hydrogen form columns successively, and further centrifugation at 1000 g for 30 seconds.
  • 25 ⁇ l of the final supernatant is added to each of 12 test tubes containing 25 ⁇ l L-arginine solution (of concentration 18 ⁇ M 'H-L-arginine, 96 nM 3 H-L-arginine) and either 25 ⁇ l of an assay buffer (50 mM HEPES. 1 M EDTA, 1.5 mM CaCl 2 , pH 7.4) or 25 ⁇ l of test compound in the buffer at 22 °C.
  • an assay buffer 50 mM HEPES. 1 M EDTA, 1.5 mM CaCl 2 , pH 7.4
  • 25 ⁇ l of test compound in the buffer at 22 °C is added 75 ⁇ l of complete assay buffer (50 mM HEPES. 1 mM EDTA. 1.5 mM CaCl 2 , 1 mM DTT.
  • Labelled L-citrulline is separated from labelled L-arginine by chromatography over a Dowex AG-50W-X8 200-400 mesh column. 1 ml of each terminated reaction is added to an individual 1 ml column and the eluant combined with that from two 1 ml distilled water washes and 16 ml of scintillation cocktail. The L- citrulline is then quantified by scintillation counting.
  • basal activity is increased by 20,000 dpm/ml of sample above a reagent blank which has an activity of 7,000 dpm/ml.
  • Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum, 4 M L-glutamine and antibiotics (100 units/ml penicillin G, 100 ⁇ g/ml streptomycin & 0.25 ⁇ g/ml amphotericin B). Cells are routinely grown in 225 cm 2 flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO : .
  • DMEM Dulbecco's Modified Eagles Medium
  • Nitric oxide synthetase is produced by cells in response to interferon-7 (IFN7) and lipopolysaccharide (LPS).
  • IFN7 interferon-7
  • LPS lipopolysaccharide
  • the medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 ⁇ g/ml LPS and 10 units/ml IFN7.
  • harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium.
  • Cells are collected by centrifugation (lOOOg for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol.
  • 25 ⁇ l substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 ⁇ Ci L-[ 3 H] arginine
  • substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 ⁇ Ci L-[ 3 H] arginine
  • the reaction is started by adding 50 ⁇ l of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50 ⁇ l of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.
  • Labelled L-citrulline is separated from labelled L-arginine using Dowex AG- 50W.
  • 150 ⁇ l of a 25% aqueous slurry of Dowex 50W (Na + form) is added to the assay after which the whole is filtered into 96 well plates.
  • 70 ⁇ l of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.
  • basal activity is 300 dpm per 70 ⁇ l sample which is increased to 1900 dpm in the reagent controls.
  • Aminoguanidine which gives an IC $0 (50% inhibitory concentration) of 10 ⁇ M, is tested as a standard to verify the procedure.
  • Enzyme may be isolated from human umbilical vein endothelial cells (HUVECs) by a procedure based on that of Pollock et al (1991 ) Proc. Nat. Acad. Sci., 88, 10480-10484.
  • HUVECs were purchased from Clonetics Corp (San Diego, CA, USA) and cultured to confluency. Cells can be maintained to passage 35-40 without significant loss of yield of nitric oxide synthetase. When cells reach confluency, they are resuspended in Dulbecco's phosphate buffered saline, centrifuged at 800 rpm for 10 mins.
  • the cell pellet homogenised in ice-cold 50 mM Tris-HCl, 1 mM EDTA, 10% glycerol, 1 mM phenvlmethylsulphonylfluoride. 2 ⁇ M leupeptin at pH 4.2. Following centrifugation at 34.000 rpm for 60 mins. the pellet is solubilised in the homogenisation buffer which also contains 20 mM CHAPS. After a 30 min incubation on ice, the suspension is centrifuged at 34.000 rpm for 30 mins. The resulting supernatant is stored at -80 °C until use.
  • 25 ⁇ l of the final supernatant is added to each of 12 test tubes containing 25 ⁇ l L-arginine solution (of concentration 12 ⁇ M 'H-L-arginine, 64 nM 3 H-L-arginine) and either 25 ⁇ l of an assay buffer (50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl 2 , pH 7.4) or 25 ⁇ l of test compound in the buffer at 22 °C.
  • an assay buffer 50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl 2 , pH 7.4
  • 25 ⁇ l of test compound in the buffer at 22 °C was added to each test tube.
  • 25 ⁇ l of complete assay buffer 50 mM HEPES. 1 mM EDTA.
  • Labelled L-citrulline is separated from labelled L-arginine by chromatography over a Dowex AG-50W-X8 200-400 mesh column. 1 ml of each terminated reaction is added to an individual 1 ml column and the eluant combined with that from two 1 ml distilled water washes and 16 ml of scintillation cocktail. The L- citrulline is then quantified by scintillation counting.
  • basal activity is increased by 5,000 dpm/ml of sample above a reagent blank which has an activity of 1500 dpm/ml.
  • Compounds may also be tested in an ex-vivo assay to determine the extent of brain penetration. Screen D
  • mice Male Sprague-Dawley rats (250-275g) were dosed intravenously at lOmg/kg with test compound dissolved in 0.9% saline or with saline alone as control. At a predetermined time (typically 2-24 hours) after treatment, the animals were sacrificed, the cerebellum removed and the supernatant prepared and assayed for nitric oxide synthetase activity as described in Screen A.
  • IC 50 the concentration of drug substance which gives 50% enzyme inhibition in the assay.
  • IC S0 values for test compounds were initially estimated from the inhibiting activity of 1, 10 and 100 ⁇ M solutions of the compounds. Compounds that inhibited the enzyme by at least 50% at 10 ⁇ M were retested using more appropriate concentrations so that an IC 50 could be determined.
  • Example 1 In Screen A above (a screen for activity against the neuronal isoform of nitric oxide synthetase), the compound of Example 1 below gave an IC 50 of less than 10 ⁇ M indicating that it is expected to show useful therapeutic activity. In Screens B and C (the screens for activity against the macrophage and endothelial isoforms of nitric oxide synthetase) the compound of Example 1 gave IC S0 values more than 10 times that obtained in Screen A indicating that it shows desirable selectivity.
  • Compounds of formula I, and pharmaceutically acceptable salts thereof, may also have the advantage that they are more selective for the neuronal isoform of nitric oxide synthetase enzyme and are therefore expected to show useful therapeutic activity with a reduced side-effect profile associated with inhibition of the other isoforms.
  • N-ff2-fPhenylmethvDamino ndan-5-ylV2-thiophenecarboximidamide dioxalate To a solution of 2-(5-aminoindanyl)-N-(phenylmethyl)trifluoroacetamide (1.0 g, 3.0 mmol) in isopropanol (6 ml)/DMF (0.5 ml) was added S-methyl-2- thiophenethiocarboximide hydroiodide (0.85 g, 3.0 mmol). The mixture was stirred for 14 hr, diluted with methanol (6 ml) and 2 N NaOH (6 ml) and heated to 50 °C for 0.5 hr.
  • Example 3 N-ff2-Amino)-l,2,3,4-tetrahvdronaphth-7-yl)-2-thiophenecarboximidamide dioxalate fa) 7-Nitro-2-amino-1.2.3,4-tetrahvdronaphthalene hvdrochloride 7-Nitro-l-tetralone (1.50 g, 7.85 mmol), ammonium acetate (6.05 ml, 78.5 mmol), acetic acid (8.0 ml), 4 A molecular sieves (20 ml), THF (15 ml) and MeOH (15 ml) were introduced into a flask and cooled to 0 °C.
  • the mixture was stirred for 14 hr, diluted with methanol (6 ml) and 2 N NaOH (6 ml) and heated to 50 °C for 0.5 hr.
  • the mixture was dumped into water and extracted with ethyl acetate ( 3 X 30 ml).
  • 7-Nitro- l-amino- 1,2,3,4-tetrahydronaphthalene was made as for 7-Nitro-2-amino- 1,2.3,4-tetrahydronaphthalene.
  • the compound was isolated as the hydrochloride salt : (0.30 g, 12%); m.p. >300 °C.
  • Example 10 The following compounds were prepared according to the method of Example 9:
  • N-f f 2-f (( 4-Phenyl)phenyl)methvQamino)indan-5-yl)-2- thiophenecarboxamidine: m.p. 182 °C.
  • Example 11 N-ff2-ff3-Chlorophenyl)methyl)amino)-1.2.3.4-tetrahvdronaphth-7-yl)-2- thiophenecarboximidamide fa) 7-Nitro-2-fff3-chlorophenyl)methyl)amino)-1.2.3.4-tetrahvdronaphthalene 7-Nitro-3,4-dihydro-2(lH)-naphthaleneone (1.50 g, 7.85 mmol), 3-chlorobenzylamine (4.70 ml, 39.3 mmol), acetic acid (6.0 ml), 4 A molecular sieves (20 ml), THF (15 ml), and MeOH (15 ml) were introduced into a flask and cooled to 0 °C.
  • 6-Acetamido-l-indanone (5.0 g, 27.6 mmol), benzylamine (3.1 ml, 27.9 mmol), and titanium isopropoxide (10.2 ml, 34.5 mmol) were combined and stirred for 1 hr.
  • the mixture was diluted with absolute ethanol (30 ml), treated with sodium cyanoborohydride (1.2 g, 19.3 mmol) and allowed to stir for 20 hr.
  • the soilds were filtered and washed with ethanol.
  • the ethanol was concentrated and the remaining oil dissolved in ethyl acetate and extracted with IN HCl ( 3 X 50 ml).
  • 6-Acetamido-(l-((phenyl)methyl)amino)indane was refluxed in 4N HCl (50 ml) for 20 min, cooled and extracted with ethyl acetate ( 3 X 50 ml). The aqueous layer was neutralized with 2N NaOH and extracted with ethyl acetate ( 3 X 100 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered and concentrated to an oil. The oil was dissolved in IPA and treated with IPA/HCl yielding the dihydrochloride salt: (2.0g, 24% for two steps); m.p. dec > 250 °C.
  • dibenzoyl-L-tartaric acid could be employed to resolve the opposite enantiomer using the same solvent system as that described above: (5.3 g, 6%), of a single isomer was obtained as determined by chiral capillary zone electrophorisis, m.p. 240-242 °C.
  • Example 17 f+)-N-ff2-ffPhenyl)methyl)amino)-1.2.3.4-tetrahvdronaphth-7-yl)-2- thiophenecarboximidamide fa) f + )-2-f f Phenyl)carbonyl)amino-7-nitroteralin
  • 2-amino-7-nitrotetralin 1.8 g, 9.39 mmol, derived from dibenzoyl-D-tartaric acid
  • THF 50 ml
  • K 2 C0 3 100 ml
  • Example 18 f-)-N-ff2-ffPhenyl)methyl)amino)-1.2.3.4-tetrahvdronaphth-7-yl)-2- thiophenecarboximidamide fa) f-)-2-ffPhenyl)carbonyl)arnino-7-nitrotetralin
  • the solid from the reaction was collected and washed with isopropanol (5 ml) and ethyl acetate (15 ml).
  • the air-dried solid weighed 1.18 g and was a mixed salt.
  • This solid was dissolved in water and was basified and extracted into ethyl acetate.
  • the solvent was dried over magnesium sulfate and concentrated to give the free base as a yellow solid.
  • the product was precipitated by the addition of ethyl acetate (35 ml).
  • the product was collected and was dried to give the product as the dihydrobromide salt (0.70 g (54%)), m.p. 281-3 °C.
  • step (a) From 7-nitro- 1,2,3,4-tetrahydroisoquinoline hydrochloride (3.00 g, 14.0 mmol) and 5% palladium on carbon (0.3 g) in ethanol (150 ml) was isolated product as a light rose colored solid (2.43 g (94%)), m.p. 232-4 °C. fb) N-f 1,2.3, 4-tetrahvdroisoquinoline-7-yl)thiophene-2-carboximidamide
  • N-fIsoquinolin-7-yl)thiophene-2-carhoximidamide fa) 7-Nitroisoquinoline A solution of 7-nitro-3,4-dihydroisoquinoline (3.00 g, 17.0 mmol) and 5 % palladium on carbon (3.0 g) in decalin (75 ml) was heated at reflux for 3 h. Upon cooling, the solution was filtered and the catalyst washed with chloroform (200 ml). The solvent was removed in vacuo to give 7-nitroisoquinoline (1.63 g) as a tan solid. MS 175
  • the solution was poured into dilute sodium hydroxide and extracted with methylene chloride.
  • the extract was dried over magnesium sulfate and the solvent evaporated to give and oil which solidified on standing.
  • the sample was purified by column chromatography on silica gel (5 % methanol in chloroform saturated with gaseous ammonia) to give 1.31 g of a solid.
  • the solid was recrystallized from ethyl acetate (25 ml) to give 1.05 g of the title compound as an off-white solid, m.p. 177.5-8.5 °C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), dans laquelle D représente un noyau aromatique hétérocyclique à cinq éléments, contenant de 1 à 4 hétéroatomes choisis parmi O, N et S, éventuellement substitués, au niveau d'un atome de carbone, par halogène, trifluorométhyle, alkyle C1 à C6, nitro ou cyano, noyau qui est relié au reste du composé de formule (I) par un atome de carbone; A représente N(X) ou CH(-(CH2)m-NXY); U représente NH, O ou CH2; V représente (CH2)a; W représente (CH2)b; a, b, m, X et Y sont tels qu'ils sont définis dans la description. L'invention concerne également des procédés de préparation de ces composés ainsi que des compositions les contenant. Les composés de formule (I) sont des inhibiteurs de la synthétase de l'oxyde nitrique et sont utiles en thérapie.
PCT/GB1995/001896 1994-05-07 1995-08-10 Derives d'amidine bicycliques utiles en therapie WO1997006158A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL95319576A PL319576A1 (en) 1995-08-10 1995-08-10 Bicyclic amidine derivatives useful in therapy
KR1019970702315A KR970706272A (ko) 1995-08-10 1995-08-10 치료에 유용한 바이시클릭 아미딘 유도체(Bicyclic Amidine Derivatives Useful in Therapy)
EE9700207A EE9700207A (et) 1995-08-10 1995-08-10 Teraapias kasutatavad bitsüklilised amidiini derivaadid
CZ19971086A CZ287969B6 (cs) 1995-08-10 1995-08-10 Amidinový derivát, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a použití
NZ290918A NZ290918A (en) 1995-08-10 1995-08-10 Bicyclic amidines
BR9509297A BR9509297A (pt) 1995-08-10 1995-08-10 Composto composição farmacêutica utilização de um composto e processos de tratamento ou prolifaxia de uma doença ou condição na qual a síntese ou suprasintese da sintetase de óxido nitrico forma uma parte contribuinte e desordens neurodegenerativas ou de enxaqueca ou de prevenção e reversão da tolerância a opiatos e diazepinas ou de tratamento do vicio em tóxicos e de preparação de um composto
SK390-97A SK281442B6 (sk) 1995-08-10 1995-08-10 Bicyklické amidínové deriváty, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie
PCT/GB1995/001896 WO1997006158A1 (fr) 1995-08-10 1995-08-10 Derives d'amidine bicycliques utiles en therapie
TW084110522A TW317565B (fr) 1994-05-07 1995-10-06
IS4452A IS4452A (is) 1995-08-10 1997-03-25 Bísýklískar amidínafleiður sem eru gagnlegar við læknismeðhöndlun

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1995/001896 WO1997006158A1 (fr) 1995-08-10 1995-08-10 Derives d'amidine bicycliques utiles en therapie

Publications (1)

Publication Number Publication Date
WO1997006158A1 true WO1997006158A1 (fr) 1997-02-20

Family

ID=10768883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001896 WO1997006158A1 (fr) 1994-05-07 1995-08-10 Derives d'amidine bicycliques utiles en therapie

Country Status (7)

Country Link
KR (1) KR970706272A (fr)
BR (1) BR9509297A (fr)
CZ (1) CZ287969B6 (fr)
EE (1) EE9700207A (fr)
IS (1) IS4452A (fr)
SK (1) SK281442B6 (fr)
WO (1) WO1997006158A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050382A1 (fr) * 1997-05-05 1998-11-12 Astra Aktiebolag Derives d'amidine utilises comme inhibiteurs de monoxyde d'azote synthase
WO1998050380A1 (fr) * 1997-05-05 1998-11-12 Astra Aktiebolag Composes
DE19844291A1 (de) * 1998-09-18 2000-03-23 Schering Ag Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln
WO2001087834A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2002064545A1 (fr) 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh Amines indanyle acyles et leurs utilisation comme agents pharmaceutiques
US6649589B1 (en) 1998-09-25 2003-11-18 A+ Science Ab (Publ) Use of certain drugs for treating nerve root injury
EP1529031A1 (fr) * 2002-08-07 2005-05-11 Aventis Pharma Deutschland GmbH Arylcycloalkylamines acylees et leur utilisation en tant qu'agents pharmaceutiques
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
EP2033953A1 (fr) 2002-02-15 2009-03-11 Glaxo Group Limited Modulateurs des récepteurs vanilloides
US7709478B2 (en) 2001-02-13 2010-05-04 Sanofi-Aventis Deutschland Gmbh Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021621A1 (fr) * 1993-03-23 1994-09-29 Astra Aktiebolag Derives de guanidine efficaces en therapeutique
WO1995005363A1 (fr) * 1993-08-12 1995-02-23 Astra Aktiebolag Derives de l'amidine ayant des activites de synthetase de l'oxyde nitrique
WO1996001817A1 (fr) * 1994-05-07 1996-01-25 Astra Aktiebolag Derives amidine bicycliques comme inhibiteurs de la synthetase de l'oxyde nitrique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021621A1 (fr) * 1993-03-23 1994-09-29 Astra Aktiebolag Derives de guanidine efficaces en therapeutique
WO1995005363A1 (fr) * 1993-08-12 1995-02-23 Astra Aktiebolag Derives de l'amidine ayant des activites de synthetase de l'oxyde nitrique
WO1996001817A1 (fr) * 1994-05-07 1996-01-25 Astra Aktiebolag Derives amidine bicycliques comme inhibiteurs de la synthetase de l'oxyde nitrique

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050380A1 (fr) * 1997-05-05 1998-11-12 Astra Aktiebolag Composes
US6166030A (en) * 1997-05-05 2000-12-26 Astra Aktiebolag Compounds
US6489322B1 (en) 1997-05-05 2002-12-03 Astrazeneca Ab Amidine derivatives as inhibitors of nitric oxide synthase
WO1998050382A1 (fr) * 1997-05-05 1998-11-12 Astra Aktiebolag Derives d'amidine utilises comme inhibiteurs de monoxyde d'azote synthase
DE19844291A1 (de) * 1998-09-18 2000-03-23 Schering Ag Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6649589B1 (en) 1998-09-25 2003-11-18 A+ Science Ab (Publ) Use of certain drugs for treating nerve root injury
WO2001087834A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
US7179839B2 (en) 2001-02-13 2007-02-20 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2002064545A1 (fr) 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh Amines indanyle acyles et leurs utilisation comme agents pharmaceutiques
AU2002253010B2 (en) * 2001-02-13 2008-02-28 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
AU2002253010B9 (en) * 2001-02-13 2008-07-31 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
RU2339614C2 (ru) * 2001-02-13 2008-11-27 Санофи-Авентис Дойчланд Гмбх Ацилированные инданиламины и их использование в качестве фармацевтических средств
AU2002253010B8 (en) * 2001-02-13 2009-04-02 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7709478B2 (en) 2001-02-13 2010-05-04 Sanofi-Aventis Deutschland Gmbh Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
US7713963B2 (en) 2001-02-13 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
KR100998161B1 (ko) * 2001-02-13 2010-12-06 사노피-아벤티스 도이칠란트 게엠베하 아실화 인다닐 아민 및 이를 포함하는 약제학적 조성물
HRP20030644B1 (en) * 2001-02-13 2012-03-31 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
US8163751B2 (en) 2001-02-13 2012-04-24 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
EP2033953A1 (fr) 2002-02-15 2009-03-11 Glaxo Group Limited Modulateurs des récepteurs vanilloides
EP1529031A1 (fr) * 2002-08-07 2005-05-11 Aventis Pharma Deutschland GmbH Arylcycloalkylamines acylees et leur utilisation en tant qu'agents pharmaceutiques

Also Published As

Publication number Publication date
BR9509297A (pt) 1998-07-07
CZ108697A3 (cs) 1998-04-15
SK39097A3 (en) 1998-08-05
KR970706272A (ko) 1997-11-03
CZ287969B6 (cs) 2001-03-14
EE9700207A (et) 1998-02-16
IS4452A (is) 1997-03-25
SK281442B6 (sk) 2001-03-12

Similar Documents

Publication Publication Date Title
EP0759027B1 (fr) Derives amidine bicycliques comme inhibiteurs de la synthetase de l'oxyde nitrique
US5807885A (en) Amidine derivatives with nitric oxide synthetase activities
EP0690851B1 (fr) Derives de guanidine efficaces en therapeutique
US5721247A (en) Isothiourea derivatives useful in therapy
AU699546B2 (en) Bicyclic isothiourea derivatives useful in therapy
WO1997006158A1 (fr) Derives d'amidine bicycliques utiles en therapie
RU2155761C2 (ru) Бициклические производные амидина, способ их получения, фармацевтическая композиция и способ ингибирования синтетазы окиси азота
IL115482A (en) Bicyclic amidine derivatives, their preparation and pharmaceutical compositions containing them
NZ290918A (en) Bicyclic amidines
HUT77376A (hu) Biciklusos amidinszármazékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA97005965A (en) Derivatives of istitiourea biciclicos, useful in tera
CZ388999A3 (cs) Sloučeniny

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95195570.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT BB BG BR BY CH CN CZ DE DK EE ES GB GE HU IS KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 290918

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 39097

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1019970702315

Country of ref document: KR

Ref document number: PV1997-1086

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970702315

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-1086

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1997-1086

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019970702315

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载